Adaptimmune Therapeutics PLC — Director's Dealing 2021

Jun 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2021-06-01

Reporting Person: Alleva Lawrence M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-01	Ordinary Shares with a nominal value of GBP0.001 per share	P	12600	$0.79	Acquired	12600	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares with a nominal value of GBP0.001 per share	60180	Indirect
Ordinary Shares with a nominal value of GBP0.001 per share	70584	Direct

Footnotes

F1: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2: The 12,600 ordinary shares reported in Column 4 and Column 5 are represented by 2,100 ADSs.

F3: The price reported in Column 4 of $0.79 per ordinary share is derived from the weighted average purchase price paid on June 1, 2021 of $4.745 per ADS divided by six.

F4: The 60,180 ordinary shares reported in Column 5 are represented by 10,030 ADSs. These shares are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust.

F5: The 70,584 ordinary shares reported in Column 5 are represented by 11,764 ADSs. These shares are held in the form of ADSs by Mr. Alleva.